SYRE vs. AKRO, ADMA, SRRK, MIRM, ACAD, ZLAB, AAPG, LNTH, TLX, and INDV
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), ACADIA Pharmaceuticals (ACAD), Zai Lab (ZLAB), Ascentage Pharma Group International (AAPG), Lantheus (LNTH), Telix Pharmaceuticals (TLX), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.
Spyre Therapeutics vs. Its Competitors
Spyre Therapeutics (NASDAQ:SYRE) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.
Akero Therapeutics' return on equity of -15.84% beat Spyre Therapeutics' return on equity.
Spyre Therapeutics has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 5 articles in the media. Spyre Therapeutics' average media sentiment score of 0.62 beat Akero Therapeutics' score of 0.55 indicating that Spyre Therapeutics is being referred to more favorably in the media.
80.4% of Spyre Therapeutics shares are owned by institutional investors. 6.2% of Spyre Therapeutics shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Spyre Therapeutics has a beta of 2.9, meaning that its share price is 190% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500.
Spyre Therapeutics presently has a consensus price target of $54.29, indicating a potential upside of 225.65%. Akero Therapeutics has a consensus price target of $81.14, indicating a potential upside of 76.24%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Spyre Therapeutics is more favorable than Akero Therapeutics.
Summary
Spyre Therapeutics beats Akero Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SYRE) was last updated on 10/6/2025 by MarketBeat.com Staff
